TwinBeech Capital’s Viridian Therapeutics VRDN Stock Holding History

TwinBeech Capital’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$647K	Sell	35,200 -41,684	-54%	-$672K	0.12%	199
2026 Q1	$1.5M	Buy	76,884 +29,203	+61%	+$867K	0.16%	191
2025 Q4	$1.48M	Buy	+47,681	New	+$1.31M	0.11%	238
2025 Q3	–	Sell	-22,417	Closed	-$313K	–	873
2025 Q2	$313K	Buy	+22,417	New	+$304K	0.01%	546
2023 Q4	–	Sell	-94,005	Closed	-$1.44M	–	922
2023 Q3	$1.44M	Buy	+94,005	New	+$1.79M	0.03%	447
2023 Q2	–	Sell	-66,612	Closed	-$1.69M	–	880
2023 Q1	$1.69M	Buy	+66,612	New	+$2.14M	0.03%	392

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

TwinBeech Capital's VRDN Position: Q2 2026 in Review

TwinBeech Capital reduced its Viridian Therapeutics (VRDN) stake by 54% in Q2 2026, selling an estimated $672K and leaving 35,200 shares worth $647K. The position accounts for 0.12% of the portfolio, ranked #199.

TwinBeech Capital first reported a position in VRDN in Q1 2023 and has held it in 6 quarters since. The position peaked at $1.69M in Q1 2023. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

TwinBeech Capital held 35,200 shares of Viridian Therapeutics worth $647K as of Q2 2026.
TwinBeech Capital sold 41,684 Viridian Therapeutics shares in Q2 2026, an estimated $672K.
Viridian Therapeutics made up 0.12% of TwinBeech Capital's portfolio in Q2 2026, its #199 holding.
TwinBeech Capital first reported a position in Viridian Therapeutics in Q1 2023 and has held it in 6 quarters since.
TwinBeech Capital's Viridian Therapeutics position peaked at $1.69M in Q1 2023.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.